BioVector® KIS-1 人弥漫大黑 B 细胞淋巴瘤细胞系 / BioVector® KIS-1 Human Diffuse Large B-Cell Lymphoma Cell Line

背景与来源说明 / Context & Provenance: BioVector® KIS-1 是一种高度特异性的恶性 B 淋巴细胞系统体外模型。该细胞系最初于 1985 年由日本科研团队从一名 53 岁患有恶性 B 细胞淋巴瘤（Ki-1 阳性弥漫大细胞淋巴瘤）的男性患者的腹水（Ascites fluid）中分离并成功建立。现已作为标准品保藏于德国微生物菌种和细胞培养物保藏中心（DSMZ），官方目录编号为 ACC 947，全球统一检索号为 Cellosaurus CVCL_M506 (RRID: CVCL_M506)。本技术档案严格基于 DSMZ 及 Cellosaurus 的权威鉴定参数进行双语编制。

通用定义BioVector® KIS-1 是一种源自人类的永生化弥漫大 B 细胞淋巴瘤（Diffuse Large B-Cell Lymphoma, DLBCL）悬浮生长型细胞系。在血液病理学、现代免疫学以及基因表达调控研究中，KIS-1 是一株极具学术代表性的特征性淋巴瘤细胞。

该细胞系在分子遗传学上最著名的特征是携带 $t(9;14)(p13;q32)$ 特异性染色体易位。该易位导致免疫球蛋白重链（IGH）增强子直接与 $PAX5$ 基因 邻近重组，从而引发 PAX5 转录因子的异常高丰度过度表达。有趣的是，尽管其源于 B 细胞谱系且 PAX5 高表达，由于缺乏关键的转录协同因子（如 EBF1），它在基线状态下天然缺失 CD19 和 CD79b 等经典 B 细胞表面标志物的表达。这一独特的「功能阻断与表型脱轨」状态，使其成为国际上研究 B 淋巴细胞终末分化障碍、转录协同复合物调控以及恶性淋巴瘤发病机制的黄金模型。

BioVector® KIS-1 技术与细胞学特征

1. 细胞形态与免疫表型特征

• 显微形态表型 属于典型的悬浮生长细胞。镜下主要表现为高度多形性（Polymorphic）的圆形或卵圆形细胞，通常以单细胞独立悬浮散在分布，或自发形成松散、易碎的小细胞丛/细胞团（Small clumps）。

• 表面免疫表型分布 根据流式细胞术（FACS）与分子免疫学测定结果：

  • 强阳性表达 CD20+, CD30+ (即 Ki-1 标志物), CD37+, CD38+, HLA-DR+, cCD79a(+), 胞质 IgG+, 胞质 κ 链与 λ 链均呈阳性信号。

  • 绝对阴性表达 CD3-, CD10-, CD13-, CD19- (关键特异性表型), CD34-, CD138-, CD80-, 胞质 IgM-。

• 分化谱系归属 其胞质内同时含有 λ 和 κ 免疫球蛋白轻链的特征表明，KIS-1 细胞可能起源于一个正在向浆细胞（Plasma Cell）方向发生终末分化演变的活化 B 淋巴细胞，但在其分化检查点发生了恶性克隆阻断。

2. 培养条件与操作指南

• 推荐基础培养基 优质的 BioVector® RPMI-1640 基础培养基（占比 80 到 90 percent）。

• 推荐血清体系 10 到 20 percent 高质量的 BioVector® Fetal Bovine Serum 胎牛血清（新复苏早期或低密度时推荐维持 20 percent，正常对数生长期可下调至 10 percent）。

• 培养环境参数 37 摄氏度，含有 5 percent 二氧化碳（CO2）的恒温恒湿培养箱。

• 倍增时间与维持丰度雷区 细胞倍增时间大约在 24 到 48 小时 之间。

  • 起始接种密度 传代分瓶时的初始接种丰度推荐控制在 $0.5\times 10^6\text{cells/mL}$ 左右。

  • 维持窗口与分瓶 日常维持培养时，必须将细胞密度牢牢锁定在 $0.1\times 10^6$ 至 $0.9\times 10^6\text{cells/mL}$ 之间。大约每 2-3 天按照 1:2 至 1:6 的比例常规分瓶或补充新鲜完全培养基。当细胞总数达到最高收获上限 $1.0\times 10^6\text{cells/mL}$ 时应立刻进行传代。

主要科研应用

1. PAX5/EBF1 协同转录复合物与表观遗传学调控

• B 细胞标志物激活模型 科研人员广泛利用 BioVector® KIS-1 作为无内源 CD19 背景的细胞沙盘。当通过多西环素（Dox）诱导恢复外源性 EBF1 表达时，能强力驱动 PAX5 募集 MLL 组蛋白 H3K4 甲基转移酶复合物（包括 KMT2A 和 MEN1），直接开启染色质转录活化，从而在体外逆转并重新激活 CD19 和 CD79b 的表达，用于解析淋巴瘤的表观遗传重塑。

2. 淋巴瘤免疫治疗与敏感性评估

• 利妥昔单抗（Rituximab）ADCC 机制 鉴于 KIS-1 细胞高表达 CD20，它被频繁用于测试针对非霍奇金 B 细胞淋巴瘤（B-NHL）的新型单克隆抗体或靶向药物。特别是用于阐明肿瘤细胞表面 ULBP 配体如何通过活化 NK 细胞的 NKG2D 受体，来介导利妥昔单抗诱导的抗体依赖性细胞介导的细胞毒作用（ADCC）。

技术指标简表

实验操作防坑指南在培养 BioVector® KIS-1 细胞时，请勿让其细胞丰度超过 $1.0\times 10^6\text{cells/mL}$ 的警戒饱和线。当细胞过度积压时，由于培养基中营养耗竭以及代谢废物的迅速累积，细胞团块会自发发生中心化坏死，导致活力出现断崖式下跌。在进行细胞计数时，若发现细胞轻微聚集，可在传代前用温和的吸管轻轻吹打数次以分散团块，切勿用力过度造成细胞机械性破碎。

BioVector® KIS-1 Human Diffuse Large B-Cell Lymphoma Cell Line

General DefinitionBioVector® KIS-1 is an immortalized human suspension cell line established from diffuse large B-cell lymphoma (DLBCL). The lineage was originally derived in 1985 from the ascites fluid of a 53-year-old male Japanese patient presenting with Ki-1-positive malignant B-cell large cell lymphoma. It is officially repository-curated by the German Collection of Microorganisms and Cell Cultures under the accession catalog number DSMZ ACC 947, and internationally cataloged under Cellosaurus CVCL_M506 (RRID: CVCL_M506). This technical data sheet is compiled utilizing authenticated baseline profiles.

In molecular hematopathology, clinical immunology, and gene transcription studies, KIS-1 represents a highly dynamic and unique aberrant B-cell model. Cytogenetically, it harbors the diagnostic $t(9;14)(p13;q32)$ chromosomal translocation, which positions the potent immunoglobulin heavy chain (IGH) enhancer adjacent to the alternative promoters of the $PAX5$ gene, thereby driving severe constitutive overexpression of the PAX5 master transcription factor. Intriguingly, despite its B-lineage origin and high PAX5 status, it natively lacks key surface markers such as CD19 and CD79b due to a lack of upstream co-activators like EBF1. This unique "blocked differentiation" signature makes it a premier global platform to decode aberrant lymphocyte maturation and transcriptional synergy.

BioVector® KIS-1 Technical & Cytological Specifications

1. Morphology and Immunophenotypic Fingerprint

• Microscopic Appearance Characterized as a suspension line. Under phase-contrast inspection, it manifests as highly polymorphic round or oval single cells growing suspended, with a natural inclination to organize into small, loosely associated clumps or aggregates.

• Immunophenotypic Profile (Surface Markers) Confirmed configurations mapped via validated DSMZ flow cytometry and immunofluorescence evaluation include:

  • Strong Positive Signatures Positive for CD20+, CD30+ (Ki-1 antigen marker), CD37+, CD38+, HLA-DR+, cCD79a(+), cytoplasmic IgG+, along with intracellular kappa (κ) and lambda (λ) light chains.

  • Absolute Negative Signatures Definitively negative for CD3-, CD10-, CD13-, CD19- (critical diagnostic anomaly), CD34-, CD138-, CD80-, and cytoplasmic IgM-.

• Lineage Placement The simultaneous internal accumulation of both kappa and lambda immunoglobulins suggests that KIS-1 represents an activated B lymphocyte caught and locked at a crucial checkpoint moving towards terminal plasma cell differentiation.

2. Cultivation & Subculturing Guidelines

• Recommended Basal Media Prepared using premium BioVector® RPMI-1640 basal medium (80 to 90 percent).

• Serum Supplementation Augmented with 10 to 20 percent certified BioVector® Fetal Bovine Serum. Higher concentrations (20%) are favored immediately post-thaw or at marginal initial densities, while 10% is sufficient for maintenance.

• Incubation Parameters 37 degrees Celsius in a humidified incubator adjusted to 5 percent Carbon Dioxide.

• Kinetic Profiles & Maintenance Densities Proliferates with a variable doubling timeframe averaging 24 to 48 hours.

  • Initial Seeding Boundary Always initiate new subcultures or seed out at approximately $0.5\times 10^6\text{cells/mL}$ to ensure adequate cell-to-cell signaling.

  • Density Control Range Maintain the viable log-phase count strictly between $0.1\times 10^6$ and $0.9\times 10^6\text{cells/mL}$ by splitting the culture 1:2 to 1:6 every 2 to 3 days. Do not allow cell accumulation to pool beyond its carrying maximum of $1.0\times 10^6\text{cells/mL}$.

Primary Research Applications

1. PAX5/EBF1 Core Regulatory Synergy & Epigenetic Mapping

• Target Transcription Reactivation Assays KIS-1 is utilized as an invaluable endogenous CD19-null platform. Ectopic restoration of EBF1 expression under doxycycline induction facilitates the recruitment of the MLL H3K4 methyltransferase complex (via KMT2A and MEN1) to PAX5 target loci, triggering epigenetic remodeling and driving robust activation of CD19 and CD79b, which models B-cell lineage remediation.

2. Evaluation of Antibody Therapeutics & ADCC Profiling

• Rituximab Mechanism Exploration Due to its stable CD20-positive status, KIS-1 cells serve as a prominent target system to assess antibody-dependent cell-mediated cytotoxicity (ADCC). It helps define how natural killer cell NKG2D receptor interaction with tumor-expressed ULBP ligands affects overall therapeutic ablation efficacy.

Technical Data Summary

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net